Search company, investor...

Singlera Genomics

singleragenomics.com

Founded Year

2014

Stage

Series B - III | Alive

Total Raised

$278.04M

Last Raised

$45.09M | 1 yr ago

About Singlera Genomics

Singlera Genomics develops a series of tumor and genetic disease detection solutions based on molecular diagnostic technology. It provides full-cycle products and services for high-incidence cancer risk assessment, early screening and diagnosis, medication guidance, and recurrence monitoring. The company was founded in 2014 and is based in Shanghai, China.

Headquarters Location

8th Floor, Building 1, Lane 500, Furonghua Road, Pudong New Area

Shanghai, Shanghai,

China

400-9204-888

Missing: Singlera Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Singlera Genomics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…

Singlera Genomics named as Highflier among 5 other companies, including Genomenon, Freenome, and Oxford Cancer Analytics.

Missing: Singlera Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Singlera Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singlera Genomics is included in 7 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,623 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

10,347 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

H

Health IT

7,901 items

Singlera Genomics Patents

Singlera Genomics has filed 4 patents.

The 3 most popular patent topics include:

  • Genetics
  • Autosomal recessive disorders
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/18/2018

Molecular biology, Transcription factors, Gene expression, Genetics, Genomics

Application

Application Date

4/18/2018

Grant Date

Title

Related Topics

Molecular biology, Transcription factors, Gene expression, Genetics, Genomics

Status

Application

Latest Singlera Genomics News

Nuance’s mysterious pricing, speedier digital health evidence reviews, and new breakthrough devices

Jun 1, 2023

Adobe You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter  delivered in your inbox every Tuesday and Thursday. An inside look at Nuance’s pricing advertisement How much is a happy doctor worth? Hospitals turn to Nuance Communications’ technology, which automatically generates medical documentation from audio recorded during patient encounters, to reduce the burden on overworked clinicians. But that technology can be very expensive, and as STAT’s Brittany Trang  reports , the investment required isn’t the same across the board. A spokesperson for Microsoft-owned Nuance attributes this to tiered pricing by which the cost for the technology “varies depending on the size of the health system and the number of users that will be set up with the system.” For the straightforwardness of that response, it’s still causing confusion and frustration among health system executives who told Brittany there is little transparency into pricing. Some — but not all — said they are being charged hefty onboarding fees or for additional licenses they aren’t using. This could prove a point of friction as Microsoft and Nuance hope to seize the current momentum around artificial intelligence. advertisement “I’m sorry to hear that this is one of the companies that’s not, if you will, offering consistent pricing for their clients. At some point, that does hurt their reputation,” said David Muntz, a health tech consultant at Starbridge Advisors. Can evidence reviews be more efficient? As digital tools pick up steam, health systems and payers often hit roadblocks thinking about how to evaluate them. “Dozens of frameworks have been proposed to assess evidence,”  writes a working group  that has proposed Evidence DEFINED, yet another framework they say addresses many of the shortcomings of previous efforts. The authors emphasize the speed of their proposed four-step process, which begins by screening interventions for “absolute requirements” like privacy and security standards and proceeds to “a streamlined approach… avoiding information gathering that may have limited value.” Absent from the plan is the common practice of creating lengthy feature lists for products, which can take more time and may produce misleading assessments. “There is often a wide gap between the minimum level of effort required to claim defensibly that a product has a given feature, and the effort required to develop the feature to a degree that contributes meaningfully to improved clinical outcomes,” write the authors, including leaders from Elevance Health, the Digital Medicine Society, and academic medical centers. Opinion: DEA’s proposed telehealth rules for addiction treatment are too stringent During the Covid-19 pandemic, the Drug Enforcement Agency loosened rules for many controlled substances, which allowed clinicians to prescribe medication that treats opioid use disorder using telehealth. With the official public health emergency now over, the agency has proposed to  extend some allowances , while adopting “appropriate safeguards.” Under the new rules, first-time patients will be able to receive a 30-day supply of buprenorphine over telehealth, after which they will need to receive treatment in person. In a STAT First Opinion, Danny Nieves-Kim, who works for addiction treatment company Bicycle Health, argues that “now is the time for advocates to demand the DEA enshrine telehealth care.” “Reverting back to primarily in-person care for opioid use disorder will only lead to more dismal statistics, eclipsing those promising recovery numbers bolstered by telehealth treatment,” he writes. The latest breakthrough devices We’ve updated our  Breakthrough Device Tracker , which keeps tabs on promising products the Food and Drug Administration has determined deserve special regulatory considerations because they might one day prove  “ more effective ” at treating or diagnosing deadly and debilitating conditions. Here are a few notable additions: ReachNeuro announced breakthrough status for its spinal cord stimulation device to treat paralysis from stroke. The company is a spin-out from a University of Pittsburgh and Carnegie Mellon lab, which  earlier this year restored hand movement for two stroke survivors . Paradromics and Cognixion each announced breakthrough designations for their brain-computer interface devices. Both are working to help patients with ALS or spinal cord injuries communicate via brain signals, though Cognixion’s device is a wearable headset. Pixium Vision earned breakthrough designation for an implant that aims to restore vision. The company will announce results of a pivotal trial at the end of the year. Two more cancer diagnostic companies revealed their breakthrough designations: Singlera Genomics for its pancreatic cancer blood test, and Promis Diagnostics for a bladder cancer urine test. A few pre-ASCO bits, plus a big fundraise Note: a few of these announcements are pegged to the American Society of Clinical Oncology conference later this week. Make sure to sign up for our  ASCO in 30 Seconds pop-up newsletter. At ASCO, Massive Bio, a platform that connects cancer patients and their oncologists to clinical trials for novel treatments, will show off ChatGPT-powered chatbots named FionaAI and Dr. ArturoAI. FionaAI is an “empathetic and knowledgeable” general bot that cancer patients seeking information about clinical trials can use. Dr. ArturoAI, meanwhile, acts as a “virtual physician” that “offers comprehensive insights into individual trials, including treatment details, schedules, nearest treatment facilities, insurance acceptance, and more.” Flatiron Health has a  new partnership  with precision medicine software company Lifebit that “will enable its researchers to securely access sensitive, real-world data on cancer patients.” Tempus, a company that combines DNA sequencing for cancer with artificial intelligence, is launching a voice-and-text assistant called Tempus One that aims to give doctors easier access to patient data. Read more here. Strive Health, a kidney care company oriented toward value-based contracting,  raised  a $166 million Series C round led by NEA with participation from CVS Health Ventures, CapitalG, Echo Ventures, Town Hall Ventures, Ascension Ventures, and Redpoint. The company said it will use the funds to expand the business. About the Author Reprints

Singlera Genomics Frequently Asked Questions (FAQ)

  • When was Singlera Genomics founded?

    Singlera Genomics was founded in 2014.

  • Where is Singlera Genomics's headquarters?

    Singlera Genomics's headquarters is located at 8th Floor, Building 1, Lane 500, Furonghua Road, Pudong New Area, Shanghai.

  • What is Singlera Genomics's latest funding round?

    Singlera Genomics's latest funding round is Series B - III.

  • How much did Singlera Genomics raise?

    Singlera Genomics raised a total of $278.04M.

  • Who are the investors of Singlera Genomics?

    Investors of Singlera Genomics include Huachen Meijing, Junci Investment, Forestone Capital, Galaxy Yuanhui, Guojing Investment and 23 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.